®()

Vyepti®(Eptinezumab-Jjmr)

Prescription Only

Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...

Dosage & Administration

Administration

Learn more.

Intravenous Infusion. Learn more.

Dosing

Learn more.

Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg . Learn more.

Latin Shorthand

Learn more.

100 mg IV infusion over ~30 mins q3mo. Some patients may benefit from 300 mg dosage.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

Learn more.

$0. Learn more.

Annual Cap

Learn more.

$200 per infusion administration fee. Learn more.

Assistance Expiration

Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

Learn more.

The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.

Mechanism of Actions (MoA)

Learn more.

CGRP Antagonist. Learn more.

Special Populations

Is it safe to use VYEPTI during pregnancy?

There is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed in animals receiving eptinezumab-jjmr at doses greater than those used clinically. Women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy, according to published data. It is important to discuss with your healthcare provider if VYEPTI is necessary during pregnancy.

Are there any risks to the fetus if the mother receives VYEPTI?

Animal studies have shown no adverse effects on embryofetal development when eptinezumab-jjmr was administered to pregnant animals at doses greater than those used clinically. However, there is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. The estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies in the U.S. general population is 2%-4% and 15%-20%, respectively.

Is it safe to breastfeed while using VYEPTI?

There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. It is important to discuss with your healthcare provider if VYEPTI is necessary while breastfeeding.

Is VYEPTI safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established for VYEPTI. It is important to discuss with your healthcare provider if VYEPTI is necessary for pediatric patients.

Is VYEPTI safe for use in geriatric patients?

Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It is important to discuss with your healthcare provider if VYEPTI is necessary for geriatric patients.

®()	Vyepti®(Eptinezumab-Jjmr)

Prescription Only	Prescription Only Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...
Dosage & Administration	Dosage & Administration comparison data
Administration
Learn more.	Intravenous Infusion. Learn more.
Dosing
Learn more.	Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg . Learn more.
Latin Shorthand
Learn more.	100 mg IV infusion over ~30 mins q3mo. Some patients may benefit from 300 mg dosage.. Learn more.
Financial Assistance	Financial Assistance comparison data
Out-Of-Pocket Costs With Copay Card
Learn more.	$0. Learn more.
Annual Cap
Learn more.	$200 per infusion administration fee. Learn more.
Assistance Expiration
Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Physician Advisory	Physician Advisory comparison data
Adverse Reactions
Learn more.	The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.
Mechanism of Actions (MoA)
Learn more.	CGRP Antagonist. Learn more.
Special Populations
	Is it safe to use VYEPTI during pregnancy? There is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed in animals receiving eptinezumab-jjmr at doses greater than those used clinically. Women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy, according to published data. It is important to discuss with your healthcare provider if VYEPTI is necessary during pregnancy. Are there any risks to the fetus if the mother receives VYEPTI? Animal studies have shown no adverse effects on embryofetal development when eptinezumab-jjmr was administered to pregnant animals at doses greater than those used clinically. However, there is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. The estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies in the U.S. general population is 2%-4% and 15%-20%, respectively. Is it safe to breastfeed while using VYEPTI? There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. It is important to discuss with your healthcare provider if VYEPTI is necessary while breastfeeding. Is VYEPTI safe for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established for VYEPTI. It is important to discuss with your healthcare provider if VYEPTI is necessary for pediatric patients. Is VYEPTI safe for use in geriatric patients? Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It is important to discuss with your healthcare provider if VYEPTI is necessary for geriatric patients.

® Alternatives